Table 1.

Hepatic porphyrin content, URO-D activity, and inhibitor activity in treated and untreated mice

Genotype	Treatment (n)	Hepatic porphyrins*	Hepatic URO-D activity†	rhURO-D inhibition, %
Uro-d+/+	None (6)	0.5 ± 0.2	1.07 ± 0.08	0.5 ± 1.4
Uro-d+/+	Fe/ALA/PCB‡ (7)	940.1 ± 95.8	0.22 ± 0.03	54.2 ± 2.0
Uro-d+/−	None (13)	0.4 ± 0.1	0.50 ± 0.04	3.1 ± 0.9
Uro-d+/−	Fe/ALA/PCB‡ (13)	1,165.1 ± 62.0	0.13 ± 0.02	49.5 ± 3.8

Numbers in parentheses indicate number of animals per group.

*nmol/g of liver, wet weight.

^†nmol of decarboxylated products per h per mg of protein.

^‡Fe/ALA/PCB, iron dextran/δ -aminolevulinic acid/polychlorinated biphenyl (Aroclor 1254).